EP1246823A1 - Pyrimidine and triazine kinase inhibitors - Google Patents

Pyrimidine and triazine kinase inhibitors

Info

Publication number
EP1246823A1
EP1246823A1 EP00990308A EP00990308A EP1246823A1 EP 1246823 A1 EP1246823 A1 EP 1246823A1 EP 00990308 A EP00990308 A EP 00990308A EP 00990308 A EP00990308 A EP 00990308A EP 1246823 A1 EP1246823 A1 EP 1246823A1
Authority
EP
European Patent Office
Prior art keywords
chosen
substituted
alkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00990308A
Other languages
German (de)
English (en)
French (fr)
Inventor
Shawn David Erickson
James Inglese
Jeffrey John Letourneau
Christopher Mark Riviello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia Drug Discovery Inc
Original Assignee
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Inc filed Critical Pharmacopeia Inc
Publication of EP1246823A1 publication Critical patent/EP1246823A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the invention relates to chemical compounds having kinase inhibitory activity and their use in the treatment of diseases and conditions associated with inappropriate kinase activity.
  • Protein kinases are key elements in signal transduction pathways responsible for transducing extracellular signals to the nuclei, triggering various biological events. [Schlessinger, J. and Ullrich, A., "Growth factor signaling by receptor tyrosine kinases," Neuron, 9:383-391 (1992)]
  • the many roles of protein tyrosine kinases (PTKs) in normal cell physiology include cell growth, differentiation, apoptosis, cell mobility and mitogenesis. [Plowman et al, "Receptor tyrosine kinases as targets for drug intervention," DN&P, 7:334- 339 (1994)].
  • Protein kinases include, for example, but are not limited to, extracellular signal- regulated kinases, p42/ERK2 and p44/ERKl; c-Jun NH 2 -terminal kinase (JNK); cAMP- responsive element-binding protein kinases (CREB); cAMP -dependent kinase (CAPK); mitogen-activated protein kinase-activated protein kinase (MAPKAP); stress-activated protein kinase p38/SAPK2; mitogen-and stress-activated kinase (MSK); pl85 ne 7Her- 2/erbB-2; platelet derived growth factor receptor kinase (PDGFR); colony stimulating factor- 1 receptor kinase (CSF1-R); endothelial growth factor receptor kinase (EGF-R); vascular endothelial growth factor kinase (VEGF-R); fibroblast growth factor receptor
  • VEGF Vascular endothelial growth factor
  • VEGF receptor tyrosine kinases have been implicated in tumor angiogenesis, psoriasis, rheumatoid arthritis, atherosclerosis, and ocular diseases. [Shawver et al., "Receptor tyrosine kinases as targets for inhibition of angiogenesis,” Drug Discovery Today, 2:50-63 (1997)]
  • JAK2 kinase myelo- and lymphoprohferative disorders [Science, 278: 1309-1312 (1997); Blood, 93:2369-2379 (1999)]; Fyn kinase: T-cell leukemia and lymphoma [Curr. Opin. Immunol., 6:372-379 (1994)]; Fgr, Lyn and Hck kinases: rheumatoid arthritis and Crone's disease [J. Exper.
  • FGFR kinase Crouzon syndrome, achondroplasia, thanatophoric dysplasia, leukemia, lymphoma and other autoimmune disorders [Nature Genetics, 8:98 (1994); Cell, 78:335 (1994); Nature Genetics, 13:233 (1996)]; ERK1 and ERK2 kinases: head and neck carcinoma [Br. J. Cancer, 80:1412-1419 (1999)]; Tie-1 and Tie-2 kinases: breast cancer [Cancer Research, 59:3185-3191 (1999); Br. J.
  • TrkA, TrkB and TrkC kinases neuroblastoma [Clin. Cancer Res., 5:1491-1496 (1999)]; IKK- ⁇ kinase: inflammation and rheumatoid arthritis [Cell, 90:373-383 (1997); Nature, 388:548-554 (1997); Published PCT application WO 99/34000]; MAPKAP kinase: inflammation and rheumatoid arthritis [Nat. Cell Biol, 1:94-97 (1999)]; p38/SAPK2 kinase: inflammation and rheumatoid arthritis [J. Bio.
  • VEGFR kinase melanoma, cancer, tumor angiogenesis, psoriasis, rheumatoid arthritis, atherosclerosis, ocular diseases and vascular disorders [Blood, 94:984-993 (1999); McMahon et al, "Protein kinase inhibitors: structural determinants for target specificity," Drug Discovery & Development, 1 : 131-146 (1998)]; HGF kinase: carcinoma and cancer [Int. J.
  • PDGF kinase chronic myelomonocytic leukemia, arteriosclerosis and fibrosis of the liver, lung and kidney [Oncogene, 7:237-242 (1992); New Engl J. Med, 314:488-500 (1986)]
  • Alk receptor kinase lymphoma [Cell, 77:307- 316 (1994); Blood, 93:3088-3095 (1999); Oncogene, 14:4035-4039 (1997)]
  • Syk kinase anaplastic large cell lymphoma [Science, 263:1281-1284 (1994); FEBSLett., 427:139-143 (1998); J. Biol.
  • Inappropriate protein kinase activities thus represent attractive targets for therapeutic intervention and in fact, several small molecule kinase inhibitor compounds have been disclosed. Natural products such as staurosporine, lavendustin A, erbstatin, genistein and flavopiridol for example, have been shown to be effective kinase inhibitors. In addition, a number of synthetic tyrosine kinase inhibitors have also been introduced. [McMahon et al, "Protein kinase inhibitors: structural determinants for target specificity," Drug Discovery & Development, 1 : 131-146 (1998)]. The present invention relates to novel compounds effective as inhibitors of inappropriate kinase activities.
  • the compounds of the present invention are effective as inhibitors of inappropriate kinase activities and therefore, are useful for the inhibition, prevention and suppression of various pathologies associated with such activities, such as, for example, inflammation, asthma, arthritis, diabetes, atherosclerosis, ocular diseases, restenosis, autoimmune responses, multiple sclerosis, psoriasis, human cancers, fibrosis of the liver, lung and kidney, transplantation rejection, and tumor metastasis.
  • the present invention provides a compound, or a salt thereof, represented by Formula I:
  • R 1 is chosen from -H, to C 20 hydrocarbon, aminocarbonylalkyl, alkoxyalkyl, substituted arylalkyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl, and substituted heterocyclylalkyl
  • R 2 is chosen from halogen, to C 20 hydrocarbon, hydroxy, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl ,
  • R 5 is chosen from -H, alkyl and substituted alkyl
  • R 6 is chosen from a direct bond, alkyl, aryl, substituted aryl and heteroaryl; and R 7 is chosen from -H, acyl, alkyl, substituted alkyl, alkoxycarbonyl, amidine, aryl, arylalkyl, heterocyclyl, heteroaryl, substituted heteroaryl, substituted
  • R 9 is chosen from -H, alkyl, substituted alkyl, aryl, heteroaryl, alkylcarbonyl and arylcarbonyl;
  • R 3 is chosen from a direct bond
  • R 4 is chosen from -H, halogen, alkyl, heterocyclyl, alkylamino, aminocarbonyl,
  • R 10 is chosen from -H, - OH, alkyl, cycloalkyl and substituted cycloalkyl;
  • R 11 is chosen from -H, - OH, - COOH, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl substituted alkyl, cycloalkyl, substituted
  • R 12 is chosen from alkyl and aryl;
  • R 13 is chosen from -H and aryl;
  • R 14 is chosen from aryl, substituted aryl, heteroaryl, substituted alkyl, aryl substituted alkyl and alkoxy substituted alkyl,
  • R 15 is chosen from alkyl, aryl, substituted aryl and substituted alkyl;
  • R 16 is chosen from aryl, substituted aryl, heteroaryl, carboxyl, alkoxy, substituted alkyl, cycloalkyl, substituted cycloalkyl, aminocarbonyl,
  • R 17 is chosen from alkyl and dialkylamino
  • R 1 is chosen from Cj toC 20 hydrocarbon and substituted arylalkyl
  • R 5 and R 7 are each -H and
  • R 6 is chosen from substituted aryl and heteroaryl
  • R 3 is chosen from and
  • R 4 is -C(0)NHR 15 wherein R 15 is substituted aryl.
  • R 1 is chosen from C, toC 20 hydrocarbon, aminocarbonylalkyl, heteroarylalkyl and substituted arylalkyl;
  • R 2 is chosen from and R """ R 6 R5 wherein
  • R 5 is chosen from -H and substituted alkyl; and R 7 is chosen from -H, - C(0)NR 8 R 9 , - C(NH)NR 8 R 9 and -NR 8 R 9 wherein R 8 is -H; and
  • R 9 is chosen from -H, alkyl, aryl and arylcarbonyl; R 3 is chosen from
  • R 4 is -H.
  • R 2 is R7 "R 6 " N R 5 wherein
  • R 5 is chosen from -H and alkyl
  • R 7 is chosen from heterocyclyl, substituted heteroaryl, -H, aryl, heteroaryl, substituted alkyl and -NR 8 R 9 wherein
  • R 8 is alkyl; and R 9 is substituted alkyl;
  • R 3 is chosen from f and
  • R 4 is chosen from - C(S)NHR 12 , - C(0)NHR 15 and - C(O)(CH 2 ) 0 . 2 R 1 wherein R 12 is aryl;
  • R 15 is substituted aryl
  • R 16 is chosen from substituted aryl and heteroaryl.
  • R 1 is chosen from C, toC 20 hydrocarbon, aminocarbonylalkyl, substituted arylalkyl, heteroarylalkyl, heterocyclylalkyl, and substituted heterocyclylalkyl;
  • R 2 is chosen from 0 ⁇ "N and R7 R ⁇ A R 5 wherein
  • R 5 is -H
  • R 7 is chosen from -H, heteroaryl, substituted heteroaryl, and -NR 8 R 9 wherein
  • R 9 is chosen from alkyl carbonyl and substituted alkyl
  • R 3 is chosen from j and
  • R 4 is chosen from - H and - C(O)(CH 2 ) 0 . 2 R 16
  • R 1 is chosen from C, toC 20 hydrocarbon, alkoxyalkyl, substituted arylalkyl, heteroarylalkyl, and substituted heterocyclylalkyl;
  • R 2 is chosen from and R " 6 R 5 wherein
  • R 5 is chosen from -H and alkyl; and R 7 is chosen from -H, heterocyclyl, substituted alkyl, heteroarylsulfonamido, dialkylsulfonamido, -NR 8 R 9 wherein
  • R 9 is chosen from alkylcarbonyl, alkyl, substituted alkyl, aryl and arylcarbonyl;
  • R 3 is chosen from a direct bond
  • R 4 is chosen from -H, (CH 2 )o- 2 R > -C(S)NHR 12 , -CHR 13 R 14 ,
  • R 10 is -H
  • R" is -H
  • R 12 is alkyl
  • R 13 is -H
  • R 14 is chosen from heteroaryl, substituted aryl and alkoxy substituted alkyl
  • R 15 is chosen from aryl and substituted aryl
  • R 16 is substituted aryl.
  • R 14 is chosen from aryl, substituted aryl, heteroaryl, substituted alkyl and aryl substituted alkyl. G) Compounds wherein: R 1 is heteroaryl;
  • R 2 is chosen from halogen and " R R ;
  • R 3 is chosen from a direct bond
  • R 4 is chosen from - C(O)(CH 2 ) 0 . 2 R 16 and .
  • inhibiting kinase activity is intended to include inhibiting, suppressing and preventing conditions associated with inappropriate kinase activity, including but not limited to, inflammation, asthma, arthritis, diabetes, atherosclerosis, ocular diseases, restenosis, autoimmune responses, multiple sclerosis, psoriasis, human cancers, fibrosis of the liver, lung and kidney, transplantation rejection, and tumor metastasis.
  • the principles of the present invention therefore also provide methods of treating a disease or condition associated with inappropriate kinase activity.
  • the methods comprise administering to a mammal in need of such treatment, an effective amount of a compound represented by Formula I , or a prodrug or salt thereof, to inhibit kinase activity, such that the activity is regulated to treat, ameliorate or prevent the disease state or condition associated with that kinase activity.
  • Such conditions include for example, but are not limited to, inflammatory and autoimmune responses, diabetes, asthma, arthritis, atherosclerosis, ocular diseases, restenosis, psoriasis, multiple sclerosis, human cancers, fibrosis of the liver, lung and kidney, inflammatory bowel disease, transplantation rejection, and tumor metastasis.
  • "treatment" of a mammal is intended to include prophylaxis and amelioration as well.
  • the compounds of the invention may be used in the manufacture of a pharmaceutical composition or medicament for the prophylactic or therapeutic treatment of disease states in mammals.
  • the compounds of the present invention may be administered as pharmaceutical compositions as a monotherapy, or in combination with other therapeutic agents, such as, for example, other antiinflammatory and or immunosuppressive agents.
  • Such other agents may include, for example, antirheumatic, steroid, corticosteroid, NSAID, antipsoriatic, bronchodilator, antiasthmatic and antidiabetic agents.
  • combination therapies can involve the administration of the various pharmaceuticals as a single dosage form or as multiple dosage forms administered at the same time or at different times.
  • Suitable routes of administration may be employed for providing a patient with an effective amount of a compound of the present invention.
  • Suitable routes of aoministration may include, for example, oral, rectal, nasal, buccal, parenteral (such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial), transdermal (such as, for example, patches), and the like.
  • parenteral such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial
  • transdermal such as, for example, patches
  • oral dosage forms such as, for example, tablets, troches, dispersions, suspensions, solutions, capsules, soft gelatin capsules, and the like, may be preferred.
  • Administration may also be by controlled or sustained release means and delivery devices. Methods for the preparation of such dosage
  • compositions incorporating compounds of the present invention may include pharmaceutically acceptable carriers or excipients, in addition to other therapeutic ingredients.
  • Excipients such as starches, sugars, microcrystalline cellulose, diluents, lubricants, binders, coloring agents, flavoring agents, granulating agents, disintegrating agents, and the like may be appropriate depending upon the route of administration. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
  • the compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic bases, and hydrates thereof.
  • base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-memyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • ATP adenosine triphosphate
  • DIEA N,N-diisopropylethylamine
  • EDTA ethylenediaminetetraacetic acid
  • HOBt 1 -hydroxybenzotriazole
  • MES 2-(N-mo holino)ethanesulfonic acid
  • ⁇ -Pr 2 NEt diisopropylethylamine
  • Pr 2 NEt dipropylethylamine
  • TBS t-butyldimethylsilyl
  • Alkyl is intended to include linear or branched hydrocarbon structures and combinations thereof of 1 to 20 carbons.
  • “Lower alkyl” means alkyl groups of from 1 to about 10, preferably from 1 to about 8, and more preferably, from 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, w-propyl, isopropyl, «-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, wo-amyl, hexyl, octyl and the like.
  • Aryl means an aromatic hydrocarbon radical of 4 to about 16 carbon atoms, preferably of 6 to about 12 carbon atoms, and more preferably of 6 to about 10 carbon atoms.
  • the rings may optionally be substituted with 1-3 substituents selected from alkyl, halogen, hydroxy, alkoxy, aryloxy, haloalkyl, phenyl and heteroaryl. Examples of aryl groups are phenyl, biphenyl, 3,4-dichlorophenyl and naphthyl.
  • Arylalkyl denotes a structure comprising an alkyl attached to an aryl ring. Examples include benzyl, phenethyl, 4-chlorobenzyl, and the like.
  • Cycloalkyl refers to saturated hydrocarbon ring structures of from 3 to 12 carbon atoms, and preferably from 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclopentylmethyl, norbornyl, adamantyl, pinanyl, myrtanyl and the like. “Lower cycloalkyl” refers to cycloalkyl of 3 to 6 carbons.
  • C j to C 20 hydrocarbon radicals include alkyl, cycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include phenethyl, cyclohexylmethyl and naphthylethyl.
  • Heterocyclyl refers to a cyclic hydrocarbon structure of from 1 to 6, preferably 5 to 6, carbon atoms, and containing from 1 to 4 heteroatoms chosen from O, N and S; or a bicyclic 9- to 10-membered heterocyclic system containing from 1 to 4 heteroatoms chosen from O, N and S.
  • Heteroaryl refers to an unsaturated cyclic hydrocarbon structure of from 1 to 6, preferably 5 to 6, carbon atoms, and containing from 1 to 4 heteroatoms chosen from O, N and S; or a bicyclic 9- or 10-membered heteroaromatic ring system containing 1-4 heteroatoms selected from O, N and S.
  • the methine H atoms of a heterocyclyl or heteroaryl structure may be optionally substituted with alkyl, alkoxy or halogen.
  • Examples include: imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole, pyrazole, pyrrolyl, pyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thiophenyl, furanyl, tetrazolyl, 2-pyrrolinyL 3-pyrrolinyl, pyrrolindinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl
  • Alkoxy means a straight, branched or cyclic hydrocarbon configuration and combinations thereof, including from 1 to 20 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably from 1 to about 4 carbon atoms, and an oxygen atom at the point of attachment. Suitable alkoxy groups include methoxy, ethoxy, w-propoxy, isopropoxy, w-butoxy, zso-butoxy, sec-butoxy, tert-butoxy, cyclopropyloxy, cyclohexyloxy, and the like. "Lower alkoxy” refers to alkoxy groups having from 1 to 4 carbon atoms.
  • Alkenyl refers to an unsaturated acyclic hydrocarbon radical in so much as it contains at least one double bond.
  • “Lower alkenyl” refers to such radicals containing from about 2 to about 10 carbon atoms, preferably from about 2 to about 8 carbon atoms and more preferably 2 to about 6 carbon atoms.
  • suitable alkenyl radicals include propenyl, buten-1-yl, isobutenyl, penten-1-yl, 2-methylbuten-l-yl, 3-methylbuten-l-yl, hexen-1-yl, hepten-1-yl, and octen-1-yl, and the like.
  • “Alkynyl” refers to an unsaturated acyclic hydrocarbon radical containing at least one triple bond. Examples include ethynyl, propynyl, and the like.
  • Substituted alkyl means an alkyl wherein at least one hydrogen attached to an aliphatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, aryl, cyano, carboxyl, alkoxycarbonyl, halogen, alkylamino, alkyloxy, alkylcyano, acetyl, hydroxyl, alkylthio, alkylsulphonyl, carboxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, and nitro.
  • substituent groups include cyano, methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, phenyl, naphthyl, chlorine, fluorine, and the like.
  • Substituted cycloalkyl means a cycloalkyl wherein at least one hydrogen attached to a ring carbon is replaced with a substituent such as alkyl, amino, alkoxy, aryl, cyano, carboxyl, alkoxycarbonyl, halogen, alkylamino, alkyloxy, alkylcyano, acetyl, hydroxyl, alkylthio, alkylsulphonyl, carboxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, and nitro.
  • a substituent such as alkyl, amino, alkoxy, aryl, cyano, carboxyl, alkoxycarbonyl, halogen, alkylamino, alkyloxy, alkylcyano, acetyl, hydroxyl, alkylthio, alkylsulphonyl, carboxyalkyl, alk
  • substituent groups include cyano, methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, phenyl, naphthyl, chlorine, fluorine, and the like.
  • “Substituted aryl” means an aryl wherein at least one methine hydrogen attached to an aromatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, aryl, acetamido, acetyl, cyano, carboxyl, alkoxycarbonyl, halogen, alkylamino, alkyloxy, alkylcyano, alkylthio, alkylsulphonyl, aminosulphonyl, carboxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, aminocarbonyl, dialkylamino, and nitro.
  • substituent groups include cyano, methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, phenyl, naphthyl, chlorine, fluorine, and the like.
  • substituent groups include aryl amides, aryl carboxylic acids, aryl carboxylic acid esters, aryl amidines, and the like, such as benzamide, benzoic acid, benzoic acid ester, benzamidine derivatives and the like.
  • Substituted heteroaryl or “substituted heterocyclyl” means a heteroaryl or heterocyclyl optionally substituted with such substituents as alkyl, amino, alkoxy, aryl, acetyl, cyano, oxo, carboxyl, alkoxycarbonyl, halogen, alkylamino, alkyloxy, alkylcyano, alkylthio, alkylsulphonyl, carboxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, and nitro.
  • substituent groups include cyano, methyl, isopropyl, methoxy, ethoxy, propoxy, amino, me ylamino, phenyl, naphthyl, chlorine, fluorine, and the like.
  • Substituted arylalkyl means an arylalkyl optionally substituted with such substituents as alkyl, amino, alkoxy, aryl, acetyl, cyano, carboxyl, alkoxycarbonyl, halogen, alkylamino, alkyloxy, alkylcyano, alkylthio, alkylsulphonyl, aminosulphonyl, carboxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, and nitro.
  • substituent groups include cyano, methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, phenyl, naphthyl, chlorine, fluorine, and the like.
  • Halogen is intended to include for example, F, Cl, Br and I.
  • prodrug refers to a chemical compound that is converted to an active agent by metabolic processes in vivo. [See, e.g., N. Boder and J.J. Kaminski, Ann. Rep. Med. Chem. 22:303 (1987) and H. Bundgarrd, Adv. Drug Delivery Rev. , 3:39 (1989)].
  • a prodrug of a compound of Formula I is intended to mean any compound that is converted to a compound of Formula I by metabolic processes in vivo.
  • the use of prodrugs of compounds of Formula I in any of the methods described herein is contemplated and is intended to be within the scope of the invention.
  • Terminology related to "protected,” “protecting” and/or “deprotecting” functionalities is used throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes which involve sequential treatment with a series of reagents.
  • a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
  • the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality.
  • the removal or "deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
  • the typical functionalities that must be protected are amines.
  • Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Protective Groups in Organic Synthesis by T.W.Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference. Particular attention is drawn to the chapter entitled "Protection for the Amino Group” (pages 309-405).
  • Preferred protecting groups include BOC and Fmoc. Exemplary methods for protecting and deprotecting with these groups are found in Greene and Wuts on pages 318 and 327.
  • solid supports The materials upon which the syntheses described herein are performed are referred to as solid supports, beads, and resins. These terms are intended to include: (a) beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N'-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; and (b) soluble supports such as polyethylene glycol or low molecular weight, non-cross-linked polystyrene.
  • the solid supports may, and usually do, have functional groups such as amino, hydroxy, carboxyl, or halo groups; where amino groups are the most common.
  • TentagelTM NH 2 (Rapp Polymere, Tubingen, Germany) is a preferred amine functionalized polyethylene glycol-grafted polystyrene resin.
  • Tentagel TM -S-PHB resin has a para-hydroxy benzyl linker which can be cleaved by the use of 90% trifluoroacetic acid in dichloromethane.
  • Techniques for functionalizing the surface of solid phases are well known in the art. Attachment of lysine to the amino groups on a bead (to increase the number of available sites) and subsequent attachment of linkers as well as further steps in a typical combinatorial synthesis are described, for example, in PCT application WO95/30642, the disclosure of which is incorporated herein by reference. In the synthesis described in WO95/30642, the linker is a photolytically cleavable linker, but the general principles of the use of a linker are well illustrated.
  • Optical Isomers - Diastereomers - Geometric Isomers Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)- , or as (£>)- or (L)- for amino acids. The present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms.
  • Optically active (R)- and (S)-, or (£>)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or optically resolved using conventional techniques.
  • any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration; thus a carbon-carbon double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.
  • the compounds of the present invention have demonstrated utility as inhibitors of inappropriate kinase activity.
  • the compounds shown in Table 1 have been synthesized according to the methods described herein and have been tested in accordance with the protocols described below. All of the compounds shown exhibited kinase inhibition with an IC 50 below lO ⁇ M.
  • Preferred compounds are those with an IC 50 below 5 ⁇ M. More preferred compounds are those with an IC 50 below 1 ⁇ M and most preferred are those with an IC 50 below 500 nM. These compounds are provided by way of illustration only, and the invention is not intended to be limited thereto.
  • Biological Assays are provided by way of illustration only, and the invention is not intended to be limited thereto.
  • Compound Preparation and Assay Format Compounds were dissolved in dimethylsulfoxide as 10 mM stock solutions. For IC 50 determinations, serial dilutions were made at 20x the final concentration used in the assay. Assays were carried out in 96-well U-bottom polypropylene microtiter plates. Jak2 Assay - Casein Substrate / Filtermat Harvest
  • the final assay volume was 60 ⁇ l, prepared by first adding 3 ⁇ l of the test compound to 27 ⁇ l of a solution containing 5 ⁇ M ATP, 10 nM [ ⁇ - 33 P]ATP and 12 ⁇ M casein in assay buffer (20 mM Tris HC1, pH 8.0, 5 mM MgCl 2 , 1 mM EDTA and 1 mM DTT), followed by 30 l of 20 nM GST-Jak2 in assay buffer. The plate was mixed by shaking and then incubated at ambient temperature for 45 min. and terminated by adding 5 ⁇ l of 0.5 M EDTA to each sample.
  • the final assay volume is 60 ⁇ l prepared from three 20 ⁇ l additions of enzyme, substrates [myelin basic protein (MBP) and ATP] and test compounds in assay buffer (50 mM Tris pH 7.5, 10 mM MgCl 2 , 50 mM NaCl and 1 mM DTT).
  • assay buffer 50 mM Tris pH 7.5, 10 mM MgCl 2 , 50 mM NaCl and 1 mM DTT.
  • Bacterially expressed, activated p38 or Erkl is pre-incubated with test compounds for 10 min. prior to initiation of reaction with substrates.
  • the reaction is incubated at 25° C for 45 min. and terminated by adding 5 ⁇ l of 0.5 M EDTA to each sample.
  • the [ ⁇ - 33 P] -incorporated MBP is harvested onto a GF/C filtermat (see below).
  • the final concentration of reagents in the assays are ATP, 1 ⁇ M; [ ⁇ - 33 P]ATP, 3 nM; MBP (bovine brain, Sigma catalog #M1891), 2 ⁇ g/well; activated p38, 10 nM; activated Erkl (Upstate Biotechnology catalog #14-188), 2.5 ⁇ g/mL, 10 nM; DMSO, 0.3%.
  • IKK- ⁇ Assay- GST-IkappaBalpha(l-54) / Filtermat Harvest The final assay volume is 60 ⁇ l prepared from three 20 ⁇ l additions of 3x GST- IkappaBalpha(l-54) in assay buffer (20 mM HEPES pH 7.6, 5 mM MgCl 2 , 50 mM NaCl, 1 mM EDTA and 1 mM DTT) plus test compound, followed by the addition of 3x baculovirus expressed IKK- ⁇ (S 177E; S 181 E) in assay buffer which is incubated for 10 min prior to initiation of reaction with a 3xATP solution (6 ⁇ M ATP and 9nM [ ⁇ - 33 P] ATP).
  • the reaction is incubated at 37°C for 30 min and terminated by harvesting onto a GF/C filtermat (see below).
  • the final concentration of reagents in the assay are ATP, 2 ⁇ M; [ ⁇ - 33 P]ATP, 3 nM; GST-IkappaBalpha (1-54), 2 ⁇ g/well; IKK- ⁇ ], 5 nM; DMSO, 0.3%.
  • the final assay volume is 50 ⁇ l prepared from two 25 ⁇ l additions of 2x GST- RbSE(768-928) in assay buffer (50 mM HEPES pH 7.5, 10 mM MgCl 2 , 2.5 mM EDTA, 10 mM ⁇ -mercaptoethanol, 2 mM DTT), 20 ⁇ M ATP, 0.125 ⁇ Ci [ ⁇ - 33 P]ATP plus test compound, followed by the addition of 2x baculovirus expressed His 6 -Cdk4/Cyclin Dl complex in assay buffer. The reaction is incubated at ambient temperature for 45 min. and terminated by addition of 50 ⁇ l of 250 mM EDTA followed by harvesting onto a GF/C filtermat (see below).
  • assay buffer 50 mM HEPES pH 7.5, 10 mM MgCl 2 , 2.5 mM EDTA, 10 mM ⁇ -mercaptoethanol, 2 mM DTT
  • 20 ⁇ M ATP 0.
  • the final concentration of reagents in the assay are ATP, 10 ⁇ M; [ ⁇ - 33 P]ATP, 10 nM (0.125 uCi); GST-RbSE(768-928), 2.5 ⁇ M; His 6 -Cdk4/Cyclin Dl complex (lO ⁇ g per well); DMSO max , 2%.
  • the final assay volume is 50 ⁇ l prepared from two 25 ⁇ l additions of 2x Histone HI in assay buffer (50 mM HEPES pH 7.5, 10 mM MgCl 2 , 2.5 mM EDTA, 10 mM ⁇ - mercaptoethanol, 2 mM DTT), 20 ⁇ M ATP, 0.125 ⁇ Ci [ ⁇ - 33 P]ATP plus test compound, followed by the addition of 2x baculovirus expressed Cdk2/ His 6 -Cyclin E complex in assay buffer. The reaction is incubated at ambient temperature for 45 min. and terminated by addition of 50 ⁇ l of 250 mM EDTA followed by harvesting onto a GF/C filtermat (see below).
  • 2x Histone HI in assay buffer 50 mM HEPES pH 7.5, 10 mM MgCl 2 , 2.5 mM EDTA, 10 mM ⁇ - mercaptoethanol, 2 mM DTT
  • 20 ⁇ M ATP 0.
  • the final concentration of reagents in the assay are ATP, 10 ⁇ M; [ ⁇ - 33 P]ATP, 10 nM (0.125 ⁇ Ci); Histone HI, 0.5 ⁇ M (1.0 ⁇ g/well); Cdk2/ His 6 -Cyclin E complex, 10 nM; DMSO max , 2%.
  • ATP 10 ⁇ M
  • [ ⁇ - 33 P]ATP 10 nM
  • Histone HI 0.5 ⁇ M (1.0 ⁇ g/well)
  • Cdk2/ His 6 -Cyclin E complex 10 nM
  • DMSO max 2%.
  • the final assay volume is 50 ⁇ l prepared from two 25 ⁇ l additions of 2x Histone (type III-SS) in assay buffer (40 mM Tris-HCl, pH 7.8, Mg(OAc) 2 ), 20 ⁇ M ATP, 0.02 ⁇ Ci [ ⁇ - 32 P]ATP plus test compound, followed by the addition of 2x baculovirus expressed Cdk2/ His 6 -Cyclin E complex in assay buffer.
  • the reaction is incubated at ambient temperature for 45 min. and terminated quenching with 50 ⁇ l of 200 mM EDTA, 75 mM phosphoric acid followed by harvesting onto a GF/C filtermat (see below).
  • the final concentration of reagents in the assay are ATP, 50 ⁇ M; [[ ⁇ - 32 P]ATP, x nM (0.02 ⁇ Ci), Histone, 2.4 ⁇ g/well; PKA, 10U (0.21 ⁇ g); DMSO max , 2%.
  • the Src kinase assay is based on the phosphorylation of a recombrnant His 6 -zeta chain substrate peptide adsorbed to a Costar 96-well microtiter plate (EIA-RIA High
  • the His 6 -zeta chain can be adsorbed to a Xenopore Nickel plate. If background is a problem, TBS supplemented with 0.02% Tween 20 can replace TBS.
  • This assay is carried out in a 50 ⁇ l volume. Plates are first coated with 8-12 ⁇ g/well zeta chain in 100 ⁇ l per well TBS and allowed to stand at 4°C overnight, followed by a 3x wash with TBS. The plates are blocked using TBS, 1%BSA, 200 ⁇ l per well at ambient temperature for 1 hr, followed by a 3x TBS wash. 25 ⁇ l of Src (100 ng/well) in assay buffer (50 mM HEPES, pH 7.5 and 10 mM MgCl 2 ), followed by addition 25 ⁇ l of test compound and 20 ⁇ M ATP in assay buffer. The reaction is allowed to proceed for 45 min. at ambient temperature with shaking.
  • the reaction is terminated by washing the plate 3x with TBS.
  • Incorporated phosphate is determined by adding 5 ng/well anti- phosphotyrosine-Eu in 100 ⁇ l of TBS, 1%BSA, 50 ⁇ M DPTA and incubating at ambient temperature with shaking for 1 hr.
  • the plate is washed 6x with TBS followed by the addition of 150 ⁇ l of enhancement buffer, shaken for 5 min. and measured on a Victor time- resolved plate reader.
  • the final concentration of reagents in the plate are Src, 0.1U (100 ng); ATP, 10 ⁇ M; DMSO, 0.5%.
  • c-Abl Assav-Biotin Peptide Substrate / NeutrAvidin Plate Capture The c-Abl kinase assay is based on the phosphorylation of a biotinylated substrate peptide bound to a NeutrAvidin (Pierce, Rockville, IL) coated flat bottom polystyrene 96- well microtiter plate. The phosphorylated peptide product is subsequently detected using an europium-labeled anti-phosphotyrosine antibody (Wallac Oy, Turku, Finland).
  • Assay plates are made 24 hours in advance of the assay by coating a Costar EIA/RIA plate with 50 ⁇ l of 2 ⁇ g/mL NeutrAvadin in TBS using the a Tomtec liquid dispenser. The plate is allowed to stand for 2 hours at ambient temperature or overnight at 4°C. The plate is washed 3x with TBS, 0.1% Tween-20 (TBST). Using the Tomtec liquid dispenser, the plate is next coated with 40 ⁇ l of 100 nM Abl biotinylated substrate peptide (Glu-Ala-Ile-Tyr-Ala-Ala-Pro-Phe- Ala-Lys( ⁇ -biotin)-NH 2 ) in TBS, 1.0% BSA. The plate is allowed to stand for 2 hours at ambient temperature or up to 1 week at 4°C, and then washed 3x with TBST.
  • TBS 0.1% Tween-20
  • the assay is carried out by the addition of 20 ⁇ l of test compound in assay buffer to the assay plate followed by addition of 40 ⁇ l of a mixture of c-Abl, ATP and anti-pY-Eu in assay buffer.
  • the final concentrations of reagents per well in solution are c-abl, 3U; ATP, 2 ⁇ M; anti-pY-Eu, 0.1 ⁇ g/mL.
  • the plate is vortexed lightly for 5 min. and the reaction is allowed to proceed for 1 hr. at ambient temperature.
  • the reaction is quenched by washing 3x with TBST.
  • Europium counts are measured following the addition of 100 ⁇ l Enhancement solution (Wallac) per well on a Victor time-resolved plate reader (Wallac).
  • VEGF Kinase Assay This assay may be used to detect VEGF binding.
  • VEGF is a peptide growth factor that binds to two structurally related tyrosine kinase receptors, Fltl and KDR.
  • Cultured human umbilical vein endothelial (HUVE) cells express two distinct populations of binding sites with affinities similar to those for Fltl and KDR, respectively.
  • the KDR expressing cells show striking changes in cell morphology, actin reorganization and membrane ruffling, chemotaxis and mitogenicity upon VEGF stimulation, whereas Fltl expressing cells lack such responses.
  • KDR undergoes ligand-induced autophosphorylation in intact cells, and both Fltl and KDR are phosphorylated in vitro in response to VEGF, however, KDR much more efficiently than Fltl .
  • Zap-70 Kinase Assay The assay is performed in black 384-well plates at a final volume of 20 ⁇ l.
  • the bacterial expressed cytoplasmic domain of human erythrocyte band 3 (cdb3) is used as a protein substrate for Zap-70 kinase.
  • the assay plates are coated with cdb3 (10 ⁇ g/mL) at 4°C overnight, and washed with TBS once.
  • 10 ⁇ l of test compounds in kinase buffer 25 mM MES, pH6.7, 10 mM MnCl 2 , 0.1% BSA and 2 ⁇ M ATP
  • the final concentration of reagents in the assays are ATP, 1 ⁇ M; MES pH 67 , 25 mM; MnCl 2 , 10 mM;
  • reaction mixture was aspirated onto a pre-wet filtermat using a Skatron Micro96 Cell Harvester (Skatron, Inc.), then washed with PBS.
  • the filtermat is then dried in a microwave oven for 1 min., treated with MeltilLex A scintillation wax (Wallac Oy, Turku, Finland), and counted on a Microbeta scintillation counter Model 1450 (Wallac). Inhibition data were analyzed by nonlinear least-squares regression using Prizm
  • Scheme 1 illustrates a solution phase synthesis via chloropyrimidines
  • Scheme 2 illustrates a solution phase synthesis via fluoropyrimidines.
  • 390 mg of the free amine 22 (1.1 mmol) is treated with 0.6 mL of ;-Pr 2 NEt and 500 mg 6- i ⁇ mdazolyl-2,4-dicMoropyrimidine (2.0 mmol) in DMF at 50 °C for 16 hr, then diluted with ethyl acetate and washed with saturated NH C1, H 2 0, brine, dried over MgS0 4 and concentrated and purification by flash chromatography (eluted with 8:10:1 EtOAc : Hexanes : MeOH) to give 23 and 24.
  • 2-amino-l-methylbenzimidazole (5.15 g, 35 mmol) was added to a solution of trifluoropyrimidine (4.40 g, 32.8 mmol) and /Pr 2 NEt (5.9 mL, 34 mmol) in CH 2 C1 2 .
  • the reaction mixture was concentrated to approximately 30 mL.
  • the two regioisomers, 2-(2-am o-l-me ylbenzirrudazole)-4,6-difluoropyrimidine 29 and 4-(2- amino-1 -methyl benzrmidazole)-2,6-difluoropyrimidine 30 were separated by silica gel chromatography (50-100% ethyl acetate in toluene). 2.04 g (23%) of the 4-substituted regioisomer and 2.17 g (25%) of the 2-substituted regioisomer were isolated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00990308A 1999-12-28 2000-12-22 Pyrimidine and triazine kinase inhibitors Withdrawn EP1246823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17322799P 1999-12-28 1999-12-28
US173227P 1999-12-28
PCT/US2000/035049 WO2001047921A1 (en) 1999-12-28 2000-12-22 Pyrimidine and triazine kinase inhibitors

Publications (1)

Publication Number Publication Date
EP1246823A1 true EP1246823A1 (en) 2002-10-09

Family

ID=22631076

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00990308A Withdrawn EP1246823A1 (en) 1999-12-28 2000-12-22 Pyrimidine and triazine kinase inhibitors
EP00988358A Expired - Lifetime EP1242385B1 (en) 1999-12-28 2000-12-22 Cytokine, especially tnf-alpha, inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP00988358A Expired - Lifetime EP1242385B1 (en) 1999-12-28 2000-12-22 Cytokine, especially tnf-alpha, inhibitors

Country Status (9)

Country Link
EP (2) EP1246823A1 (ja)
JP (2) JP2003519143A (ja)
AT (1) ATE449764T1 (ja)
AU (2) AU2457201A (ja)
CA (2) CA2396693A1 (ja)
DE (1) DE60043397D1 (ja)
ES (1) ES2335265T3 (ja)
IL (1) IL150420A0 (ja)
WO (2) WO2001047921A1 (ja)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
CN100355750C (zh) 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
WO2002036578A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
EP1341773A2 (en) * 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
WO2002059110A1 (en) 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
CA2672805A1 (en) * 2001-01-31 2002-08-08 H. Lundbeck A/S Pyrimidine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
KR100798579B1 (ko) * 2001-03-31 2008-01-28 동화약품공업주식회사 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
DE60235470D1 (de) * 2001-06-26 2010-04-08 Pharmacopeia Inc N-heterocyclische inhibitoren der expression von tnf-alpha
CA2451128A1 (en) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
JP2005511509A (ja) * 2001-09-21 2005-04-28 レディ ユーエス セラピューティクス インコーポレイテッド 新規トリアジン化合物の方法および組成物
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
EP1441683A4 (en) * 2001-10-12 2005-10-26 Univ New York TRISUBSTITUTED TRIAZINE COMPOUNDS WITH ANTI-TUBULIN ACTIVITY, METHODS OF MAKING AND USING SAME
HUP0402106A3 (en) * 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2002357033B2 (en) * 2001-11-30 2009-05-07 Synta Pharmaceuticals Corporation Pyrimidine compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1490354A1 (en) 2002-03-09 2004-12-29 Astrazeneca AB 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
KR100516434B1 (ko) 2002-04-04 2005-09-22 (주) 비엔씨바이오팜 6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040082627A1 (en) * 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
SI1534286T1 (sl) * 2002-07-29 2010-04-30 Rigel Pharmaceuticals Inc Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
KR101297924B1 (ko) * 2002-07-29 2013-08-20 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법
DE60330466D1 (de) * 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
EP1543009A4 (en) * 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazine KINASE INHIBITORS
WO2004031184A1 (en) * 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
CN1781019A (zh) * 2003-03-12 2006-05-31 萨马里坦药品公司 模拟神经系统疾病的动物模型
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
NZ545270A (en) 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
GB0323137D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W 2,4,6- Trisubstituted pyrimidines and their different uses
EP1682495A1 (en) 2003-10-21 2006-07-26 Warner-Lambert Company LLC Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
DK1687297T3 (da) * 2003-11-24 2014-09-22 Prometic Biosciences Inc Triazindimerer til behandling af autoimmunsygdomme
EP1689740A1 (en) 2003-11-24 2006-08-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
CA2556239A1 (en) * 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
PT1730146E (pt) * 2004-03-30 2011-07-11 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
JP4560329B2 (ja) * 2004-05-07 2010-10-13 全薬工業株式会社 ５−アミノピリミジン化合物
ATE434614T1 (de) * 2004-06-28 2009-07-15 Bayer Schering Pharma Ag 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
CA2579143A1 (en) 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
EP1799218A1 (en) 2004-09-30 2007-06-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
JP2008515984A (ja) 2004-10-13 2008-05-15 ワイス Ｐｉ３ｋ阻害剤としての１７−ヒドロキシワートマニンの類似体
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
US7662837B2 (en) 2004-10-22 2010-02-16 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
EP1807077B1 (en) * 2004-10-22 2016-11-23 Janssen Pharmaceutica NV Inhibitors of c-fms kinase
ES2380550T3 (es) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
SI1846394T1 (sl) 2005-02-04 2012-06-29 Astrazeneca Ab Pirazolilaminopiridinski derivati uporabni kot kinazni inhibitorji
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
CA2602294C (en) 2005-03-25 2015-02-24 Tibotec Pharmaceuticals Ltd. Heterobicylic inhibitors of hvc
WO2006105222A2 (en) * 2005-03-25 2006-10-05 Scios Inc. Carboxamide inhibitors of tgfb
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
WO2006123113A2 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
AU2006259525B2 (en) * 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
US7592451B2 (en) 2005-06-23 2009-09-22 New York University Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
EP1928862A1 (en) * 2005-09-13 2008-06-11 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
BRPI0616722A2 (pt) 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
AU2006307657B2 (en) 2005-10-28 2010-10-28 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ATE508126T1 (de) * 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
CA2821517A1 (en) * 2005-12-01 2007-06-07 Basf Se Process for producing nitrobenzoyl chloride
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
UA95940C2 (uk) 2006-01-17 2011-09-26 Вертекс Фармасьютикалс Інкорпорейтед Азаіндоли як інгібітори кіназ януса
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
AU2007240439B2 (en) 2006-04-20 2012-10-11 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
JP5331680B2 (ja) 2006-04-20 2013-10-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
AR061974A1 (es) * 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
EP2046763A2 (en) 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
WO2008016675A1 (en) * 2006-08-01 2008-02-07 Praecis Pharmaceuticals Incorporated P38 kinase inhibitors
US9987277B2 (en) 2006-10-04 2018-06-05 Janssen Sciences Ireland Uc Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
CA2699718C (en) 2007-09-21 2014-05-27 Array Biopharma Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2009050120A1 (de) 2007-10-12 2009-04-23 Basf Se Verfahren zur herstelung von sulfonsäurediamiden
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2008340421B2 (en) * 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
US7923450B2 (en) 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
CN101952275B (zh) 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
KR101579999B1 (ko) * 2008-04-21 2015-12-23 타이젠 바이오테크놀러지 컴퍼니 리미티드 헤테로사이클릭 화합물
MY158927A (en) 2008-06-12 2016-11-30 Janssen Pharmaceutica Nv Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
WO2010026096A1 (de) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh 7-(piperazin-1-ylmethyl)-1h-indol-2-carbonsäure (phenyl) -amidderivate und verwandte verbindungen als p38 map-kinase-inhibitoren zur behandlung von atemwegserkrankungen
CN102203064A (zh) 2008-09-02 2011-09-28 贝林格尔.英格海姆国际有限公司 新的苯甲酰胺，其制备及其作为药物的用途
CA2736924C (en) 2008-10-09 2016-06-28 F. Hoffmann-La Roche Ag Modulators for amyloid beta
KR101293421B1 (ko) 2008-11-10 2013-08-05 에프. 호프만-라 로슈 아게 헤테로사이클릭 감마 분비효소 조절제
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
US8497276B2 (en) 2009-03-31 2013-07-30 Arqule, Inc. Substituted indolo-piperidine compounds
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
KR20120034726A (ko) * 2009-06-08 2012-04-12 아브락시스 바이오사이언스, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
JP2012529517A (ja) * 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
WO2010148197A1 (en) 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
AU2011246067A1 (en) * 2010-04-28 2012-09-27 Daiichi Sankyo Company, Limited [5,6] heterocyclic compound
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
AU2011289604C1 (en) 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
NZ609957A (en) 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
CN103347866B (zh) 2010-11-29 2016-05-18 加林制药公司 作为治疗呼吸控制不适或疾病的呼吸兴奋剂的新化合物
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
EP2691384B1 (en) * 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
FR2983859B1 (fr) * 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
SG11201405692UA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Salts of an epidermal growth factor receptor kinase inhibitor
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
WO2013138793A2 (en) * 2012-03-16 2013-09-19 Maraxi, Inc. Affinity reagants for protein purification
AU2013299922B2 (en) 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
US9624180B2 (en) * 2013-01-25 2017-04-18 Bristol-Myers Squibb Company Squaric derivatives for the treatment of hepatitis C
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
JP2016515105A (ja) * 2013-03-07 2016-05-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎の処置のためのピリミジン化合物
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015054317A1 (en) * 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR102400737B1 (ko) 2014-03-14 2022-05-20 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
PL3177612T3 (pl) 2014-08-04 2022-08-08 Nuevolution A/S Opcjonalnie skondensowane pochodne pirymidyny podstawione heterocyklilem, użyteczne w leczeniu chorób zapalnych, metabolicznych, onkologicznych i autoimmunologicznych
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
EP4403173A3 (en) 2015-10-15 2024-10-09 Les Laboratoires Servier Combination therapy for treating malignancies
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
CN105384702B (zh) * 2015-12-11 2018-04-10 浙江大学 三取代均三嗪类化合物及其制备方法
CN105399695B (zh) * 2015-12-11 2019-04-19 浙江大学 三嗪类化合物及其制备方法和用途
US10604492B2 (en) * 2015-12-24 2020-03-31 The Regents Of The Universtiy Of California CFTR regulators and methods of use thereof
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2019040919A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California OCULAR PHARMACEUTICAL COMPOSITIONS
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
JP7390487B2 (ja) * 2019-12-03 2023-12-01 サムジン ファーマシューティカル カンパニー，リミテッド 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3157653A (en) * 1960-11-22 1964-11-17 Ciba Ltd Sulfatoalkylamino derivatives of triazine and pyrimidine vat dyestuff
CH672923A5 (ja) * 1986-06-07 1990-01-15 Sandoz Ag
JPH01247467A (ja) * 1988-03-30 1989-10-03 Toyo Ink Mfg Co Ltd 顔料分散剤および顔料組成物
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5733932A (en) * 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000506532A (ja) * 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
IT1284525B1 (it) * 1996-09-13 1998-05-21 3V Sigma Spa Derivati di benzossazolo loro uso come stabilizzanti contro le radiazioni uv
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
AR038955A1 (es) * 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
WO1999001442A1 (en) * 1997-07-02 1999-01-14 Zeneca Limited Triazine derivatives and their use as antibacterial agents
EP1042276B1 (en) * 1997-12-23 2004-11-17 Warner-Lambert Company Llc Thiourea compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
EP1053230A1 (en) * 1998-01-13 2000-11-22 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
FR2775434B1 (fr) * 1998-02-27 2000-05-19 Oreal Compositions cosmetiques pour la photoprotection de la peau et/ou des cheveux a base d'un melange synergique de filtres et utilisations
ITMI981266A1 (it) * 1998-06-05 1999-12-05 3V Sigma Spa Derivati 1,3,5-trianilinotriazinici come filtri contro le radiazioni solari uv-b
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0147921A1 *

Also Published As

Publication number Publication date
ES2335265T3 (es) 2010-03-24
JP2003519130A (ja) 2003-06-17
CA2396693A1 (en) 2001-07-05
AU2457201A (en) 2001-07-09
IL150420A0 (en) 2002-12-01
WO2001047921A1 (en) 2001-07-05
JP4794793B2 (ja) 2011-10-19
CA2394727A1 (en) 2001-07-05
EP1242385A1 (en) 2002-09-25
JP2003519143A (ja) 2003-06-17
EP1242385B1 (en) 2009-11-25
ATE449764T1 (de) 2009-12-15
WO2001047897A1 (en) 2001-07-05
AU2735201A (en) 2001-07-09
DE60043397D1 (de) 2010-01-07

Similar Documents

Publication Publication Date Title
EP1246823A1 (en) Pyrimidine and triazine kinase inhibitors
US20050277642A1 (en) Pyrimidine kinase inhibitors
JP7337951B2 (ja) 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体
US20220162203A1 (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
EP3746072B1 (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
NO177054B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminopyrimidinderivater
WO2016054987A1 (zh) Egfr抑制剂及其制备和应用
WO2019034128A1 (zh) 吡咯并三嗪类衍生物、其制备方法及其用途
JP2008534597A (ja) ＰＫＣ−θのインヒビターとして有用なピリジン誘導体
EP3971190A1 (en) Heterocycle-fused pyrimidine derivative and use thereof
US10159663B2 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016026423A1 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
CA2703767A1 (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
JP2014526526A (ja) リゾホスファチジン酸（ｌｐａ）受容体アンタゴニストとしてのベンジルピペリジン化合物
TWI819470B (zh) Fgfr激酶抑制劑及其應用
CN111499613B (zh) N-甲酰胺衍生物、其制备方法及其在医药上的用途
EA023146B1 (ru) Производные пиразолидин-3-она
CN111153889B (zh) 2-吲哚酮-三唑类抗肿瘤化合物及其制备方法和应用
CN115894381B (zh) 一种2,4,5-三取代嘧啶类化合物及其制备方法和用途
CN108912098B (zh) 一种嘧啶类化合物及应用
US7638518B2 (en) Substituted pyrazole kinase inhibitors
CN113336774B (zh) 作为trk抑制剂的取代的手性二芳基大环化合物
CN111362924B (zh) 氘代的嘧啶衍生物及其用途
WO2019096112A1 (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
CN116283920B (zh) 2,4-二取代吡啶类化合物及其应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACOPEIA DRUG DISCOVERY, INC.

17Q First examination report despatched

Effective date: 20050316

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051129

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1051530

Country of ref document: HK